EUVIMEDEUVIMED entdecken
KorrekturOpen Access · CC BY 4.0

Correction: Exploring factors predicting the effectiveness of oral semaglutide in Japanese individuals with type 2 diabetes switching from dipeptidyl peptidase 4 inhibitors: a pilot study

Takao Hirotsu, Kanta Taniguchi, Rimei Nishimura

Frontiers in Clinical Diabetes and Healthcare · 06.07.2026 · 7

DOI: 10.3389/fcdhc.2026.1914250 ↗

Kurz gefasst

Korrektur in der Zeitschrift Frontiers in Clinical Diabetes and Healthcare, online erschienen am 06.07.2026. Verfasst von Takao Hirotsu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes, Endocrinology and Hematology, Fuji Municipal Central Hospital, Fuji, Japan. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Correction on: Hirotsu T, Taniguchi K and Nishimura R (2025). Exploring factors predicting the effectiveness of oral semaglutide in Japanese individuals with type 2 diabetes switching from dipeptidyl peptidase 4 inhibitors: a pilot study. Front. Clin. Diabetes Healthc. 6:1520389. doi: 10.3389/fcdhc.2025.1520389Adding/removing text In the published article, one of the eligibility criteria for the patients included in the study was not stated with the same level of detail as in the IRB-approved protocol. A correction has been made to the Methods section, subsection Patients, Paragraph 1: "iii) those who had previously received DPP-4 inhibitors and were deemed by their treating physicians to require transition to a GLP-1 receptor agonist, subsequently initiated oral semaglutide at a starting dose of 3 mg, and, at an outpatient follow-up visit conducted at least 12 weeks after initiation, had no adherence-or tolerability-related barriers to continued treatment;"The original version of this article has been updated.

Schlagwörter

Stichwörter der Autor:innen

DPP-4 inhibitorsGLP-1 receptor agonistsalcohol drinkingsmokingtype 2 diabetes

Autor:innen und Institutionen

  • Department of Diabetes, Endocrinology and Hematology, Fuji Municipal Central Hospital, Fuji, Japan.
  • Department of Internal Medicine, Taniguchi Medical Clinic, Fujinomiya, Japan.
  • Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine, Minato, Japan.

Zitieren

APA

Hirotsu, T., Taniguchi, K., & Nishimura, R. (2026). Correction: Exploring factors predicting the effectiveness of oral semaglutide in Japanese individuals with type 2 diabetes switching from dipeptidyl peptidase 4 inhibitors: a pilot study. Frontiers in Clinical Diabetes and Healthcare, 7. https://doi.org/10.3389/fcdhc.2026.1914250

Vancouver

Hirotsu T, Taniguchi K, Nishimura R. Correction: Exploring factors predicting the effectiveness of oral semaglutide in Japanese individuals with type 2 diabetes switching from dipeptidyl peptidase 4 inhibitors: a pilot study. Frontiers in Clinical Diabetes and Healthcare. 2026;7. doi:10.3389/fcdhc.2026.1914250

BibTeX
@article{Hirotsu2026,
  author = {Hirotsu, Takao and Taniguchi, Kanta and Nishimura, Rimei},
  title = {Correction: Exploring factors predicting the effectiveness of oral semaglutide in Japanese individuals with type 2 diabetes switching from dipeptidyl peptidase 4 inhibitors: a pilot study},
  journal = {Frontiers in Clinical Diabetes and Healthcare},
  year = {2026},
  volume = {7},
  doi = {10.3389/fcdhc.2026.1914250}
}
Kostenlos starten →